Concordia International Corp. is changing its name to Advanz Pharma following its recapitalization.

In September, Concordia completed its recapitalization, reducing the company's outstanding debt by about $2.4 billion.

With the new Advanz Pharma brand, the company aims to bring sustainable value to customers, healthcare providers and patients through its portfolio of specialty generic as well as legacy branded, off-patent medicines.

The Canadian specialty pharmaceutical company's name change is expected to be effective in the fourth quarter, pending customary approvals, including stock exchange and shareholder approvals.